Global Anal & Colorectal Cancer Market 2020-2026
発行: Orion Market Research Pvt Ltd
Global Anal & Colorectal Cancer Market Size, Share & Trends Analysis Report by Treatment (Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Hospitals, Ambulatory Surgery Centers, and Cancer Research Centers) Forecast Period 2020-2026
The global anal & colorectal cancer market is anticipated to grow at a considerable CAGR during the forecast period. Colorectal cancer is a malignant tumor that starts in the cells of the colon or the rectum while it takes place in the anus in case of anal cancer. The rising prevalence of anal and colorectal cancer due to poor lifestyles such as obesity and tobacco consumption has created a demand for its treatment which, in turn, is driving the market growth. Colorectal cancer is the third most common malignancy and the fourth leading cause of cancer-related mortalities globally. As per the World Health Organization (WHO), in 2020, the number of colorectum cancer of mortality of male and female of all ages was around 935,173 across the globe, which is 9.4% of total mortalities. Additionally, the number of new colorectum cancer patients of both sexes of all ages in 2020 was around 1.9 million globally, which is 10.0% of new cancer cases.
As per the American Cancer Society, around 9,090 new cases of anal cancer are expected in the US in 2021, of which 6,070 in women and 3,020 in men. Besides, around 1,430 mortalities of anal cancer are expected in 2021. Apart from it, around 104,270 new cases of colon cancer and around 45,230 new cases of rectal cancer are expected in the US in 2021. Furthermore, the increasing geriatric population which is more prone to colorectal cancer is another factor driving the market growth. However, the high cost of anal and colorectal cancer treatment along with low awareness towards this type of cancer act as major restraints for the market growth. However, increasing healthcare expenditure, technological advancement for cancer treatment, and rising demand for anal and colorectal cancer treatment are expected to drive the market especially in developing countries.
The global anal and colorectal cancer market is segmented based on treatment and end-user. Based on the treatment, the market is segmented into radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Based on end-users the market is segmented into hospitals, ambulatory surgery centers, and cancer research centers. Hospitals held a major market share in 2019 based on end-user. The factors such as rising quality assessment in hospitals, growing colorectal cancer cases among individuals, and increasing demand for minimal complication rates in surgery of special colorectal cancer are anticipating driving the growth of this market segment.
The global anal & colorectal cancer market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America has been predicted to dominate the global anal & colorectal cancer market. The high prevalence of anal & colorectal cancer cases in the US along with easy access of US citizens to its treatment due to the presence of well-established healthcare infrastructure is anticipated to drive the growth of this regional growth of market.
Global Anal & Colorectal Cancer Market Growth by Region, 2020-2026
Source: OMR Global
Asia-Pacific is Projected to Exhibit Considerable Growth in the Global Anal & Colorectal Cancer Market
Asia-Pacific is anticipated to exhibit considerable growth in the global anal & colorectal cancer market during the forecast period. The rising geriatric population which is prone to cancer coupled with the increasing incidence and prevalence rate of anal & colorectal cancer are the factors driving the regional growth of the market. As per the WHO, in 2020, in Asia-pacific, around 569,186 incidences of colon cancer were recorded, which is 49.6% of total cases across the globe. Besides, around 296,236 mortalities were recorded due to colon cancer in 2020, which was around 51.4%. Apart from this, the number of anal cancer patients in 2020 was 16,645, and mortalities were 8,120 in the region.
Market Players Outlook
Some of the key players of the anal & colorectal cancer market include Amgen Inc., Taiho Pharmaceutical Co., Ltd, F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.
The Report Covers